Efficacy and tolerability of eslicarbazepine acetate as monotherapy in patients of newly diagnosed focal epilepsy

Introduction Eslicarbazepine Acetate, a novel anti-epileptic drug has been approved as monotherapy in focal onset seizures, with/without secondary generalization adults. many advantages over older drugs and is useful patients of new epilepsy. Objectives Aim our study was to determine the efficacy safety observe its well-tolerated use monitor adverse effects newly diagnosed Methods Study done at Department Psychiatry, Teerthanker Mahaveer University, Moradabad. A total 30 cases epilepsy between 18-60 years age were studied for 6 months, using Semi-structured Interview Liverpool Adverse Events Profile. Results Majority males (58%), 21-30 years. Patients with partial/focal seizures (63%) more common than those generalized (37%). participants had 1-2 episodes weekly(48%), while some almost daily(32%). on Acetate 800 mg two divided doses daily (64%), others received 1200 three doses(32%). The mean Profile score initially 28.34 ± 6.28 which significantly improved after 4 weeks treatment 22.80 4.35 (p < 0.05). improvement other No major side observed. Conclusions effective treating Better results this are found patients. Disclosure significant relationships.